 TEL AVIV, Israel, Jan. 27, 2021 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Companys proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-19. The study will assess the ability of VB-201 to prevent clinical deterioration and reduce morbidity and mortality in patients with severe COVID-19. 